Key result
MEDEA tests dabigatran switch or tranexamic acid vs continuing FXa inhibitors for heavy menstrual bleeding.
Why the study?
Direct comparisons between factor Xa inhibitors and thrombin inhibitors for heavy menstrual bleeding, as well as prospective efficacy and safety data on adding tranexamic acid during anticoagulation, were lacking.
Does switching to dabigatran or adding tranexamic acid reduce heavy menstrual bleeding in premenopausal women on factor Xa inhibitors?
RCT
Open-label
randomized
Does switching to dabigatran or adding tranexamic acid reduce heavy menstrual bleeding in premenopausal women on factor Xa inhibitors?
Answers are grounded in this paper and cite their sources.
The MEDEA study will evaluate whether switching to dabigatran or adding tranexamic acid improves heavy menstrual bleeding in premenopausal women on factor Xa inhibitors.
BACKGROUND: In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA). Treatment with the direct oral thrombin inhibitor dabigatran appears to be associated with a reduced risk of HMB compared with VKA. These findings come from small observational studies or post hoc analyses of trials in which HMB was not a primary outcome. Use of tranexamic acid during the menstrual period may be effective in patients with HMB, but prospective data regarding efficacy and safety in patients on anticoagulant treatment are lacking. RATIONALE AND DESIGN: A direct comparison of a factor Xa inhibitor and a thrombin inhibitor with HMB as primary outcome, as well as an evaluation of the effects of adding tranexamic acid in women with anticoagulant-associated HMB is highly relevant for clinical practice. The MEDEA study is a randomized, open-label, pragmatic clinical trial to evaluate management strategies in premenopausal women with HMB associated with factor Xa inhibitor therapy. OUTCOMES: Women using factor Xa inhibitors with proven HMB, as assessed by a pictorial blood loss assessment chart (PBAC) score of >150, will be randomized to one of three study arms: (i) switch to dabigatran; (ii) continue factor Xa inhibitor with addition of tranexamic acid during the menstrual period; or (iii) continue factor Xa inhibitor without intervention. The primary outcome is the difference in PBAC score before and after randomization. Here, we present the rationale and highlight several unique features in the design of the study.
No takes yet. Share an insight, caveat, or question.
Hamulyák et al. (2020) conducted an RCT in Heavy menstrual bleeding associated with factor Xa inhibitor therapy. Switch to dabigatran or addition of tranexamic acid vs. Continue factor Xa inhibitor without intervention was evaluated on Difference in PBAC score before and after randomization. The MEDEA study is a randomized, open-label trial designed to evaluate switching to dabigatran or adding tranexamic acid versus continuing factor Xa inhibitors for heavy menstrual bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: